Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma

Por Barth, Matthew J., Mavis, Cory, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J.
Publicado no Clin Cancer Res (2015)

Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice

Por Chu, Yaya, Yahr, Ashlin, Huang, Brian, Ayello, Janet, Barth, Matthew, S. Cairo, Mitchell
Publicado no Oncoimmunology (2017)

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children’s Oncology Group (COG) report

Por Barth, Matthew J., Goldman, Stanton, Smith, Lynette, Perkins, Sherrie, Shiramizu, Bruce, Gross, Thomas G., Harrison, Lauren, Sanger, Warren, Geyer, Mark B., Giulino-Roth, Lisa, Cairo, Mitchell S.
Publicado em 2013

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Por Czuczman, Natalie M., Barth, Matthew J., Gu, Juan, Neppalli, Vishala, Mavis, Cory, Frys, Sarah E., Hu, Qiang, Liu, Song, Klener, Pavel, Vockova, Petra, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J.
Publicado no Blood (2016)

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children’s Oncology Group Report

Por Goldman, Stanton, Smith, Lynette, Galardy, Paul, Perkins, Sherrie L., Frazer, J. Kimble, Sanger, Warren, Anderson, James R., Gross, Thomas G., Weinstein, Howard, Harrison, Lauren, Shiramizu, Bruce, Barth, Matthew, Cairo, Mitchell S.
Publicado em 2014

A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential p...

Por Awasthi, Aradhana, Rolland, Delphine C.M., Ayello, Janet, van de Ven, Carmella, Basrur, Venkatesha, Conlon, Kevin, Fermin, Damian, Barth, Matthew J, Klein, Christian, Elenitoba-Johnson, Kojo S.J., Lim, Megan S., Cairo, Mitchell S.
Publicado no Oncotarget (2017)

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: A Children’s Oncology Group Pilot Study Report...

Por Shiramizu, Bruce, Goldman, Stanton, Smith, Lynette, Agsalda-Garcia, Melissa, Galardy, Paul, Perkins, Sherrie L., Frazer, J. Kimble, Sanger, Warren, Anderson, James R., Gross, Thomas G., Weinstein, Howard, Harrison, Lauren, Barth, Matthew J., Mussolin, Lara, Cairo, Mitchell S.
Publicado no Br J Haematol (2015)

Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma

Por Giulino-Roth, Lisa, van Besien, Herman J., Dalton, Tanner, Totonchy, Jennifer E., Rodina, Anna, Taldone, Tony, Bolaender, Alexander, Erdjument-Bromage, Hediye, Sadek, Jouliana, Chadburn, Amy, Barth, Matthew J., Dela Cruz, Filemon S., Rainey, Allison, Kung, Andrew L., Chiosis, Gabriela, Cesarman, Ethel
Publicado no Mol Cancer Ther (2017)

Genomewide Linkage Analysis of Quantitative Spirometric Phenotypes in Severe Early-Onset Chronic Obstructive Pulmonary Disease

Por Silverman, Edwin K., Palmer, Lyle J., Mosley, Jonathan D., Barth, Matthew, Senter, Jody M., Brown, Alison, Drazen, Jeffrey M., Kwiatkowski, David J., Chapman, Harold A., Campbell, Edward J., Province, Michael A., Rao, D. C., Reilly, John J., Ginns, Leo C., Speizer, Frank E., Weiss, Scott T.
Publicado em 2002